Nestlé plays down big deals
This article was originally published in OTC Bulletin & The Rose Sheet
Nestlé chief executive officer Mark Schneider has hinted that a move for either Pfizer’s or Merck KGaA’s OTC business is not realistic so soon after signing a deal to snap up dietary supplements specialist Atrium Innovations.
You may also be interested in...
Sanofi seeks to delay decision clearing path for Mylan's Lantus biosimilar; says it should be able to get rehearing based on Federal Circuit's ruling that PTAB judges were not constitutionally appointed.
First Circuit reverses dismissal of direct purchasers' suit alleging improper listing of patent on device drive mechanism delayed competition; district court to decide if this constitutes antitrust violation.
Brands unfairly maligned by powerful influencers, strictly on behalf of paying competitors, could have occasion to broach the subject with the US Federal Trade Commission, which seeks comment on its “Endorsement Guides” in an increasingly complex and competitive, digitized advertising environment.